Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ:ALVO)

8.570 -0.700 (-7.55%)
Streaming Delayed Price Updated: 1:24 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 64,211
Open 8.880
Bid (Size) 8.560 (2)
Ask (Size) 8.590 (1)
Prev. Close 9.270
Today's Range 8.550 - 8.880
52wk Range 9.150 - 14.76
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer
From Alvotech
Via GlobeNewswire
Alvotech Reports Record Results for 2024 and Provides Business Update
From Alvotech
Via GlobeNewswire

Performance

YTD
-34.9%
-34.9%
1 Month
-20.7%
-20.7%
3 Month
-34.9%
-34.9%
6 Month
-30.3%
-30.3%
1 Year
-26.7%
-26.7%

More News

Read More
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Earnings Scheduled For November 13, 2024
Via Benzinga
Alvotech's Earnings Outlook
Via Benzinga
Earnings Scheduled For March 26, 2025
Via Benzinga
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)
From Alvotech
Via GlobeNewswire
Alvotech Strengthens Biosimilar Portfolio With $27 Million Xbrane R&D Deal
Via Benzinga
Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
From Alvotech
Via GlobeNewswire
Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
From Alvotech
Via GlobeNewswire
Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida
From Alvotech
Via GlobeNewswire
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
From Teva Pharmaceutical Industries Ltd; Alvotech
Via GlobeNewswire
Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
From Alvotech
Via GlobeNewswire
JB Hunt Transport Posts Weak Earnings, Joins JetBlue Airways And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
From Alvotech
Via GlobeNewswire
Alvotech Reports Financial Results for the First Nine Months of 2024
From Alvotech
Via GlobeNewswire
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
From Alvotech
Via GlobeNewswire
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
From Alvotech
Via GlobeNewswire
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
From Alvotech
Via GlobeNewswire
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
From Alvotech
Via GlobeNewswire

Frequently Asked Questions

Is Alvotech - Ordinary Shares publicly traded?
Yes, Alvotech - Ordinary Shares is publicly traded.
What exchange does Alvotech - Ordinary Shares trade on?
Alvotech - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Alvotech - Ordinary Shares?
The ticker symbol for Alvotech - Ordinary Shares is ALVO on the Nasdaq Stock Market
What is the current price of Alvotech - Ordinary Shares?
The current price of Alvotech - Ordinary Shares is 8.570
When was Alvotech - Ordinary Shares last traded?
The last trade of Alvotech - Ordinary Shares was at 04/04/25 01:24 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.